Children's Medical Center Corporation

Philip Rotner serves as Chief Investment Officer and established the investment office in 2010. He reports to President and CEO Kevin Churchwell, who leads both CMCC and Boston Children's Hospital. Rotner's external roles — including service on the Massachusetts PRIM Investment Committee and a strategic advisory position at Windrose Advisors — suggest significant autonomy in manager selection and direct investment decisions.

The investment office leverages Boston Children's Hospital's research community and its Harvard Medical School affiliation to identify life-science managers and co-investment opportunities. Scientific founders like Timothy Springer, who has licensed intellectual property to the hospital, create a diligence pipeline that generic allocators cannot replicate. Rotner's external board seats at PRIM and Windrose Advisors provide additional institutional and family-office deal flow.

CMCC is the corporate parent and sole member of Boston Children's Hospital, making it closer in structure to a health-system holding company than a standalone university endowment. The investment office runs an in-house portfolio that blends fund commitments across venture, buyout, and distressed strategies with direct co-investments — a deployment model that resembles a foundation's investment office more than a typical hospital treasury function.

Yes. CMCC controls real estate assets through Fenmore Realty Corporation, with a portfolio that includes the hospital's main Longwood Avenue campus, a satellite facility in Waltham, and the Franciscan Hospital for Children campus in Brighton. These are held as commercial operating assets separate from the financial investment portfolio.

Philanthropic gifts flow through separate entities — primarily Boston Children's Hospital Trust and the CHMC Anesthesia Foundation — that are structurally distinct from CMCC's investment pool. This separation ensures that donor-restricted charitable funds are not commingled with the assets Rotner manages for the corporation's balance sheet.

The strategy spans the full venture lifecycle: seed-stage, start-up, early-stage, expansion, and late-stage. The office participates through both fund commitments to external venture managers and direct co-investments, giving Rotner the flexibility to back companies at formation or support later rounds alongside trusted GPs.

CMCC operates a hybrid model. The office commits capital to external funds across venture, buyout, growth, distressed debt, and special situations strategies, while also maintaining a direct co-investment capability. This dual approach allows Rotner to access manager-curated portfolios and selectively increase exposure to specific companies through side-by-side direct investments.